

Figure S1. (a) Chromium release assay (18 hour) using MC38-Ova cells as targets and OT-I T-cells as effectors (0.1:1), in the presence of the indicated concentrations of birinapant (b) Chromium release assay (18 hour) using MC38-Ova cells as targets and and treated with TNF (2 ng/ml), in the presence of the indicated concentrations of birinapant. Data representative of 3 individual experiments. (c) Chromium release assay (18 hour) using MC38-Ova cells as targets and OT-I T-cells as effectors, in the presence or absence of BV6 (1 μ M). (d) Chromium release assay (18 hour) using HeLa cells as targets and KHYG1 NK cells as effectors, in the presence or absence of BV6 (1 μ M). Error bars represent the mean \pm S.E.M. of triplicate determinations from a representative experiment (n=3), *p < 0.05 by unpaired Student's t test.




Figure S2. MC38-Ova cells were exposed to OT-I T-cells at the indicated effector to target (E:T) ratio. After either 6 hours or 18 hours, cytokines in supernatants were measured by CBA. Data is representative of three individual experiments.




Figure S3. Pooled data (n=3) from key representative experiments shown in main figures, see main figures for experimental details. *p < 0.05 by unpaired Student's t test.

Supplementary Movie

Supplementary movie. MC38-Ova cells were seeded in chamber slides, then overlaid with perforin deficient OT-I T-cells. T-cells were labeled with cell trace violet (CTV). A cleaved caspase3/7 reporter and birinapant (1 μ M) was added to the co-culture media. Cells were incubated for 8 hours at 37°C/10% CO₂. Optical sections were acquired through sequential scans or Brightfield/DIC on a confocal microscope using a 40X (NA 0.85) air objective.